Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
APREPITANT RMB, APREPITANT SCP (Southern Cross Pharma Pty Ltd)
Product name
APREPITANT RMB, APREPITANT SCP
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
117 working days (255)
Active ingredients
aprepitant
Registration type
New generic medicine
Indication
APREPITANT RMB, APREPITANT SCP (capsules) in combination with other antiemetic agents, are indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:
- highly emetogenic cancer chemotherapy.
- moderately emetogenic cancer chemotherapy.
APREPITANT RMB, APREPITANT SCP are indicated for the prevention of postoperative nausea and vomiting.